Searched for
BIOSIMILAR RANIBIZUMAB
Zydus Lifesciences shares soar 7% to fresh record high after Q4 results. Should you buy, sell or hold?Zydus Lifesciences shares climbed to a new 52-week high. The company reported a 9% rise in net profit and over 16% revenue growth for the J...- Lupin ties up with Sandoz to commercialise biosimilar productLupin has partnered with Sandoz Group AG to commercialize its biosimilar ranibizumab across multiple regions, with Sandoz handling commerci...
- Lupin inks licensing deal to supply biosimilar ranibizumab in Latin AmericaLupin, an Indian drug maker, partners with SteinCares. The agreement focuses on ranibizumab's commercialisation. Latin America, excluding M...
- Lupin ties up with Amman Pharma for commercialisation of biosimilar productLupin has inked a licensing pact for the commercialisation and marketing of Ranibizumab, a biosimilar of Lucentis, in various countries inc...
- Alkem Laboratories Q2 Results: Net profit up 77% YoY at Rs 615 croreTotal expenses in the quarter were marginally higher at Rs 2,797.66 crore, as against Rs 2,727.71 crore in the same period a year ago, the ...
- Lupin's JV completes global trials for RA biosimilarThe randomised trial of 52 weeks was conducted in 11 countries and included over 500 patients, Lupin said.
- Make in India: Can India be a hub for the $200 billion worth biosimilars opportunityThe Indian biogenerics industry is poised to exploit the opportunity they did in the case of generics, although it has no clear advantage a...
- How Dr Reddy’s is rebooting its biosimilars playDr Reddy’s was among the first to race off the blocks with four launches in India about as many years. But things have slowed since.
- Intas Pharmaceuticals to launch its first biosimilar in US in 9-12 monthsIntas is the only domestic firm with two biosimilars filed for registration in the US and it looks to deliver affordable and innovative pha...
Load More
